Acute Heart Failure Clinical Trial
— EMPA-AHFOfficial title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Empagliflozin in Patients With Acute Heart Failure
The EMPA-AHF trial is a multicentre, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of early initiation of once-daily oral empagliflozin 10 mg in patients hospitalized for patients with acute heart failure (AHF) who are at a high risk of adverse events.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | June 30, 2025 |
Est. primary completion date | March 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 89 Years |
Eligibility | Inclusion Criteria: Patients who meet the below inclusion criteria will be randomized within 12 h after presentation to the hospital 1. Age of =20 and <90 years 2. Hospitalized with a diagnosis of acute heart failure, requiring intravenous loop diuretic therapy, and with all of the following characteristics: i. Dyspnoea at rest or induced by slight exertion ii. At least two of the following findings: jugular venous distention, pulmonary rales, lower leg edema, and pulmonary congestion on chest X-ray iii. If the patient has a sinus rhythm at the time of admission, BNP =350 pg/mL or NT-proBNP =1400 pg/mL; if the patient has atrial fibrillation at the time of admission, BNP =500 pg/mL or NT-proBNP =2000 pg/mL. For patients taking an angiotensin receptor neprilysin inhibitor, only the reference value for NT-proBNP will be applicable. 3. At least one of the following characteristics: i. eGFR <60 mL/min/1.73m2, as calculated using the CKD Epidemiology Collaboration for JapaneseModification of Diet in Renal Disease formula ii. Already taking =40 mg of oral furosemide during the period before hospitalization. For patients on loop diuretics other than furosemide, the following conversion should be used: oral furosemide 20 mg = oral azosemide 30 mg = oral torasemide 5 mg. iii. Urine output of <300 mL during the 2 h following an appropriate dose of intravenous furosemide administered after hospitalization. An appropriate dose of intravenous furosemide is 20 mg for patients who have not been taking furosemide regularly before hospitalization and is the same as, or greater than, the daily oral dose for patients who have been taking furosemide regularly before hospitalization. 4. Provided written consent to participate in the study Exclusion Criteria: 1. eGFR <20 mL/min/1.73m2 at the time of admission 2. Already taking an SGLT2i within 3 months prior to hospitalization 3. Type 1 diabetes mellitus 4. Systolic blood pressure <90 mmHg 5. Expected to newly require treatment with thiazide, tolvaptan, or carperitide within 48 h after hospitalization 6. Main cause of acute heart failure hospitalization is not fluid retention (e.g., persistent ventricular tachycardia, persistent atrial fibrillation/atrial flutter with a ventricular response rate of =130 bpm, persistent bradycardia with a ventricular response rate of <45 bpm, an infection, severe anemia, and an acute exacerbation of COPD) 7. Acute coronary syndrome, pulmonary thromboembolism, or a cerebrovascular accident is the main cause of the present hospitalization. 8. At risk of ketoacidosis or hyperosmolar hyperglycaemia 9. On dialysis, including peritoneal dialysis, or the initiation of dialysis during hospitalization is planned 10. Pregnant or lactating women 11. Underwent the following therapeutic interventions within 30 days: cardiovascular surgery (e.g., coronary artery bypass grafting, surgery for valvular heart disease, transcatheter aortic valve implantation, percutaneous coronary intervention, percutaneous edge-to-edge mitral valve repair, and other types of surgery at the investigator's discretion) and implantation of an implantable defibrillator, cardiac resynchronization therapy defibrillator, or implantable ventricular-assist device 12. A diagnosis of acute coronary syndrome, cerebral infarction, or transient ischemic attack made within 90 days 13. Ventricular tachycardia with syncope within 90 days 14. Heart transplant recipient or listed for heart transplantation and expected to undergo transplantation during the present treatment; implanted with an implantable ventricular-assist device or expected to require an implantable ventricular-assist device during the present treatment; or expected to switch to palliative care 15. Intubated at the time of screening or expected to require intubation within 48 h after hospitalization 16. Severe valvular heart disease expected to be treated with thoracostomy or catheterization (a reason to exclude secondary mitral or tricuspid regurgitation due to reduced cardiac function does not exist, except for the absence of a plan to perform cardiac surgery or therapeutic catheterization) 17. A diagnosis of secondary cardiomyopathy such as amyloidosis, cardiac sarcoidosis, hemochromatosis, Fabry disease, and muscular dystrophy. Heart failure due to takotsubo cardiomyopathy, obstructive hypertrophic cardiomyopathy, complex congenital heart disease (as determined by the investigator), or pericardial constriction. 18. A diagnosis of peripartum cardiomyopathy made within 6 months 19. Active myocarditis 20. Presence of uncontrolled thyroid disease 21. Acute cardiac structural abnormalities (e.g., acute mitral regurgitation due to ruptured chordae tendineae) 22. Symptomatic bradycardia or complete atrioventricular block, being treated with a temporary pacemaker implantation at the time of admission, or expected to require a temporary pacemaker implantation in the future. Patients who have already been treated with a permanent pacemaker implantation do not meet the exclusion criteria. 23. Serious liver disorder (an increase in AST, ALT, or ALP level =3 times the upper limit of normal) or cirrhosis with varices or other findings suggestive of portal hypertension 24. Alcohol use disorder of at least mild severity according to the DSM-V 25. A diagnosis of active malignancy or suspected active malignancy made within 2 years 26. Coexisting diseases other than heart failure with an expected survival prognosis of =1 year 27. Participation in a clinical study of another drug 30 days before hospitalization 28. Patients considered to require fasting at screening. 29. Other conditions likely to interfere with the patient's safety or compliance with the protocol 30. Other patients who are considered unsuitable by the principal investigator or other investigators |
Country | Name | City | State |
---|---|---|---|
Japan | Nishiarai Hospital | Adachi | Tokyo |
Japan | Anjo Kosei Hospital | Anjo | Aichi |
Japan | Fukuokaken Saiseikai Futsukaichi Hospital | Chikushino | Fukuoka |
Japan | Mitsui Memorial Hospital | Chiyoda | Tokyo |
Japan | Sakakibara Heart Institute | Fuchu | Tokyo |
Japan | Japanese Red Cross Fukuoka Hospital | Fukuoka | |
Japan | Funabashi Municipal Medical Center | Funabashi | Chiba |
Japan | Tokyo Medical University Hachioji Medical Center | Hachioji | Tokyo |
Japan | Hyogo Brain and Heart Center | Himeji | Hyogo |
Japan | Hirosaki University Hospital | Hirosaki | Aomori |
Japan | Hiroshima City Hospital | Hiroshima | |
Japan | Tokai University Hospital | Isehara | Kanagawa |
Japan | Juntendo University Shizuoka Hospital | Izunokuni | Shizuoka |
Japan | Kameda Medical Center | Kamogawa | Chiba |
Japan | Nara Medical University Hospital | Kashihara | Nara |
Japan | Kasukabe Chuo General Hospital | Kasukabe | Saitama |
Japan | Saitama Medical Center | Kawagoe | Saitama |
Japan | Kawaguchi Cardiovascular and Respiratory Hospital | Kawaguchi | Saitama |
Japan | St.Marianna University School of Medicine Hospital | Kawasaki | Kanagawa |
Japan | Chikamori Hospital | Kochi | |
Japan | Kurume University Hospital | Kurume | Fukuoka |
Japan | Gunma University Hospital | Maebashi | Gunma |
Japan | International University of Health and Welfare Mita Hospital | Minato | Tokyo |
Japan | Toranomon Hospital | Minato | Tokyo |
Japan | Iwate Prefectural Cyuou Hospital | Morioka | Iwate |
Japan | Nagoya University Hospital | Nagoya | Aichi |
Japan | Kochi Medical School Hospital | Nankoku | Kochi |
Japan | Nara Prefecture General Medical Center | Nara | |
Japan | Sakakibara Heart Institute of Okayama | Okayama | |
Japan | Nakagami Hospital | Okinawa | |
Japan | Kitano Hospital | Osaka | |
Japan | Osaka General Medical Center | Osaka | |
Japan | Kindai University Hospital | Osakasayama | Osaka |
Japan | Saitama Citizens Medical Center | Saitama | |
Japan | Sapporo Higashi Tokushukai Hospital | Sapporo | Hokkaido |
Japan | Tokyo Women's Medical University Hospital | Shinjuku | Tokyo |
Japan | Soka City Hospital | Soka | Saitama |
Japan | National Cerebral and Cardiovascular Center Hospital | Suita | Osaka |
Japan | Hyogo Prefectural Awaji Medical Center | Sumoto | Awaji |
Japan | National Disaster Medical Center | Tachikawa | Tokyo |
Japan | Tokushima University Hospital | Tokushima | |
Japan | Juntendo University Hospital | Tokyo | |
Japan | Juntendo University Nerima Hospital | Tokyo | |
Japan | Nihon University Itabashi Hospital | Tokyo | |
Japan | Tokyo Medical University | Tokyo | |
Japan | Tokyo Metropolitan Bokutoh Hospital | Tokyo | |
Japan | Tsuchiura Kyodo General Hospital | Tsuchiura | Ibaraki |
Japan | Urasoe General Hospital | Urasoe | Okinawa |
Japan | Juntendo University Urayasu Hospital | Urayasu | Chiba |
Japan | Saiseikai Utsunomiya Hospital | Utsunomiya | Tochigi |
Japan | Yokohama City University Medical Center | Yokohama |
Lead Sponsor | Collaborator |
---|---|
Juntendo University | Boehringer Ingelheim |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | A hierarchical composite endpoint consisting of death within 90 days, heart failure rehospitalization within 90 days, WHF during hospitalization, and urine output up to 48 hours after treatment initiation, assessed by the win ratio | WHF, worsening heart failure | Up to 90 days | |
Secondary | A hierarchical composite endpoint consisting of death within 90 days, heart failure readmission within 90 days, and WHF during hospitalization | WHF, worsening heart failure | Up to 90 days | |
Secondary | A composite endpoint consisting of WHF during hospitalization, death, heart failure rehospitalization, urgent visit for WHF, intensification of diuretic therapy, and worsening NYHA class within 90 days | WHF, worsening heart failure | Up to 90 days | |
Secondary | Change in NT-proBNP from randomization to 48 hours | Evaluated at 48 hours after randomization | ||
Secondary | Diuretic response, calculated as urine output achieved by loop diuretics (40 mg intravenous furosemide-equivalent dose) at 48 h after treatment initiation | Evaluated at 48 hours after randomization | ||
Secondary | Improvement in KCCQ-TSS of =5 points from randomization to 30 and 90 days after treatment initiation | KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire - Total Symptom Score. The scores range from 0 to 100, with 100 being the best possible score. | Up to 90 days | |
Secondary | Time to hemodynamic stabilization during index hospitalization | During index hospitalization | ||
Secondary | Re-worsening of heart failure during index hospitalization | During index hospitalization | ||
Secondary | Heart failure rehospitalization | Up to 90 days | ||
Secondary | Death | Up to 90 days | ||
Secondary | Urine output during the 48 h after randomization | Evaluated at 48 hours after randomization | ||
Secondary | Cardiovascular death | Up to 90 days | ||
Secondary | Change in the visual analog scale score for dyspnea from after randomization to 24 and 48 h | The scores range from 0 to 100, with 100 being the best possible score. | Evaluated at 24 and 48 hours after randomization | |
Secondary | Change in high sensitivity cardiac troponin T | Evaluated at 48 hours after randomization | ||
Secondary | Change in the KCCQ-TSS after randomization to 30 and 90 days | KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire - Total Symptom Score. The scores range from 0 to 100, with 100 being the best possible score. | Up to 90 days | |
Secondary | Composite of renal replacement therapy, renal transplantation, eGFR <15 mL/min/1.73m2, =50% decrease in eGFR compared to the first sample or a =2-fold increase in creatinine level compared to the first sample within 90 days of randomization | Up to 90 days | ||
Secondary | Trend in eGFR after randomization to 24 h, 48 h, 30 days, and 90 days | Up to 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02151383 -
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
|
Phase 2 | |
Completed |
NCT02135835 -
A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure
|
Phase 4 | |
Recruiting |
NCT05556044 -
Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction
|
Phase 3 | |
Recruiting |
NCT04363697 -
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
|
Phase 4 | |
Completed |
NCT02122640 -
Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department
|
N/A | |
Not yet recruiting |
NCT01211886 -
Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)
|
N/A | |
Completed |
NCT01193998 -
Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
|
N/A | |
Not yet recruiting |
NCT06465498 -
Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography
|
N/A | |
Recruiting |
NCT05276219 -
Optimized Treatment of Pulmonary Edema or Congestion
|
Phase 4 | |
Recruiting |
NCT03157219 -
Manipal Heart Failure Registry (MHFR)
|
N/A | |
Completed |
NCT06024889 -
Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure.
|
Phase 1/Phase 2 | |
Terminated |
NCT04174794 -
Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
|
||
Recruiting |
NCT05972746 -
Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure
|
N/A | |
Enrolling by invitation |
NCT02258984 -
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
|
N/A | |
Completed |
NCT02141607 -
Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
|
||
Completed |
NCT01870778 -
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
|
Phase 3 | |
Recruiting |
NCT05986773 -
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance
|
Phase 4 | |
Recruiting |
NCT04163588 -
Sequential Nephron Blockade in Acute Heart Failure
|
Phase 3 | |
Recruiting |
NCT03717636 -
Early or Non-revoked in Hospital-day in Patients With Acute Heart Failure
|
N/A | |
Recruiting |
NCT03720288 -
Acetazolamide in Patients With Acute Heart Failure
|
Phase 3 |